HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice - Episode 11

Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC

, , , ,

Focusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.

EP. 1: Challenges in Diagnosing HER2+ Breast Cancer
EP. 2: Neoadjuvant Treatment Options in HER2+ Early Breast Cancer
EP. 3: Preoperative Monitoring and Surgical Options for HER2+ Patients
EP. 4: Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer
EP. 5: Standard-of-Care Regimens for First-Line Treatment of HER2+ mBC
EP. 6: Ongoing Clinical Trials in HER2+ Metastatic Breast Cancer
EP. 7: Impact of DESTINY-Breast09 and Other Trials on Clinical Practice and Patient Subsets
EP. 8: Defining HER2 Low and HER2 Ultra-Low: Diagnostic Challenges
EP. 9: Overview of DESTINY-Breast06
EP. 10: Clinical Perspectives on Managing ILD Related to T-DXd
Now Viewing
EP. 11: Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC
EP. 12: Unmet Needs and Future Direction in HER2+ Breast Cancer

Video content above is prompted by the following question:

  • What has been your practice patterns and experience in sequencing ADCs for metastatic HER2-low and HER2+ mBC?